Kips Bay Fires Staff, Cuts Costs To Keep eSVS Mesh In The Game
This article was originally published in The Gray Sheet
The company is downsizing to keep its clinical trial for its eSVS Mesh product on track. It estimates it currently has enough funds to last it through the year, but cautions it may take months to gather patient follow-up data.
You may also be interested in...
Kips Bay Liquidates As Its Bypass Graft Device Shows Poorly In Study
The struggling Minnesota company made a last-ditch effort to complete the eMESH 1 trial of the eSVS Mesh device for coronary artery bypass graft surgery, but the firm, founded by device sector luminary Manny Villafana, has decided to give it up after the early results from the trial proved disappointing.
Kips Bay Medical IPO Will Fund U.S. Trial Of Bypass Graft-Protecting Mesh
Kips Bay Medical plans to begin patient enrollment later this year for a U.S. trial of a mesh sleeve designed to improve the performance of coronary artery bypass grafts
Keytruda, Opdivo May Be Only Part B Drugs Chosen For Medicare Negotiation In First Applicable Year
In general, more Part D drugs will be eligible than Part B drugs in the early years of the program because Part D drugs have higher levels of spending and so will dominate the list of candidates. A new report sizes up the drugs that would qualify for Medicare Price negotiation in 2026-2028.